logo-loader

Pharmaxis' CEO Gary Phillips updates on partnership with Boehringer Ingelheim

Published: 08:25 08 Sep 2017 AEST

Pharmaxis will receive €10 million milestone payment when the first patient is dosed in this 2nd indication Phase IIa study.

Syntara to start Phase 2 study targeting MDS

Syntara Ltd (ASX:SNT) CEO Gary Phillips joins Proactive’s Jonathan Jackson to share insights on the company's expansion of its lead drug, SNT-5505, into new medical indications, including a promising Phase 2 study targeting myelodysplastic syndrome (MDS). Phillips highlighted the significance of...

on 14/2/24